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Abstract
Aims: To undertake a Priority Setting Partnership (PSP) to establish priorities for 
future research in diabetes and pregnancy, according to women with experience of 
pregnancy, and planning pregnancy, with any type of diabetes, their support networks 
and healthcare professionals.
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1 |  INTRODUCTION
Approximately one in every 10 women will experience 
a pregnancy complicated by either pre- existing or ges-
tational diabetes.1 Rates are increasing as a result of in-
creased rates of obesity and pregnancy at a later age.2 
Although most women have healthy pregnancies and 
healthy babies, diabetes increases the risk of complica-
tions during pregnancy and birth, and can have long- term 
effects. Compared to the maternity population without 
diabetes, the risks are two to six times greater for adverse 
outcomes such as congenital anomalies, stillbirth, preterm 
birth, infant death within the first month of life, together 
with long- term risks of adverse cardiovascular outcomes 
in both mothers and children.3,4
Many pregnant women with diabetes report a lack or in-
consistency of information, leaving many of their questions 
unanswered. National guidelines and high- quality system-
atic reviews highlight variable quality, heterogeneity and 
reliability of research. Consequently, treatment guidelines 
are insufficiently evidenced in line with current context and 
available healthcare options.5,6 However, with limited fund-
ing and resources available for research, it is important to 
ensure that the research that is undertaken is of highest value 
and impact.
Healthcare research led by industry and researchers 
often does not address the issues that are most important 
for people living with the condition, or those who support 
them.7 The James Lind Alliance (JLA), a UK- based ini-
tiative established in 2004, aims to address this mismatch. 
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Methods: The PSP used established James Lind Alliance (JLA) methodology work-
ing with women and their support networks and healthcare professionals UK- wide. 
Unanswered questions about the time before, during or after pregnancy with any type 
of diabetes were identified using an online survey and broad- level literature search. 
A second survey identified a shortlist of questions for final prioritisation at an online 
consensus development workshop.
Results: There were 466 responses (32% healthcare professionals) to the initial sur-
vey, with 1161 questions, which were aggregated into 60 unanswered questions. 
There were 614 responses (20% healthcare professionals) to the second survey and 18 
questions shortlisted for ranking at the workshop. The top 10 questions were: diabetes 
technology, the best test for diabetes during pregnancy, diet and lifestyle interven-
tions for diabetes management during pregnancy, emotional and well- being needs of 
women with diabetes pre- to post- pregnancy, safe full- term birth, post- natal care and 
support needs of women, diagnosis and management late in pregnancy, prevention of 
other types of diabetes in women with gestational diabetes, women's labour and birth 
experiences and choices and improving planning pregnancy.
Conclusions: These research priorities provide guidance for research funders and 
researchers to target research in diabetes and pregnancy that will achieve greatest 
value and impact.
K E Y W O R D S
diabetes mellitus, health priorities, perinatal care, post- natal care, pregnancy, prenatal care, 
researchNovelty statement
• Women report a lack of consistent evidence- based information to help them man-
age their diabetes in the period before to after pregnancy.
• The top 10 questions for research in diabetes and pregnancy according to women, 
their support networks and healthcare professionals were identified.
• Joint top priorities for research were diabetes technology and identifying the best 
test for diabetes in pregnancy.
• These questions will inform funders of research and researchers towards addressing 
areas of great need and impact.
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Through Priority Setting Partnerships (PSP), the JLA sup-
ports the identification of the research questions that matter 
most to patients and the healthcare professionals that care 
for them. Sharing the outputs of PSPs with health research 
funders helps to align the work they fund towards address-
ing the areas of need prioritised by those directly affected 
and involved.
Previous successful PSPs have been conducted in diabetes 
in the UK. The type 1 diabetes PSP identified two questions 
in pregnancy, but both fell outside the top 10 priorities: ‘What 
impact do changing hormones, for example, during menstrua-
tion, pregnancy and menopause, have on blood glucose levels 
in women with type 1 diabetes?’; ‘Is it safe to continue insulin 
analogues in preconception and pregnancy in type 1 diabe-
tes?’8 No priorities specific to pregnancy were identified in 
the type 2 diabetes PSP top 10.9 There have also been prioriti-
sation exercises using different but overlapping methodology 
to PSPs in Canada and  the USA but focussing on gestational 
diabetes.10,11 However, women's health and pregnancy, par-
ticularly in relation to diabetes, are not prioritised, despite 
being consistently identified as an area of much needed 
research.2,12,13
A PSP was therefore established between the University 
of Oxford, Diabetes UK, Diabetes Research and Wellness 
Foundation, JDRF the type 1 diabetes charity, and JLA, on 
World Diabetes Day 2018. The PSP aimed to find out the 
priorities for future research in diabetes and pregnancy, ac-
cording to women and their support networks (families, part-
ners, friends and carers) with experience of pregnancy, or 
planning pregnancy, with any type of diabetes and healthcare 
professionals.
2 |  PARTICIPANTS AND METHODS
The PSP employed the established JLA methodology.14
2.1 | Establishing the PSP
The PSP was overseen by a steering group representing key 
stakeholders (Supplementary Table S1) and was chaired by a 
senior JLA advisor to ensure transparency of the process, and 
fair and equal involvement of all members. The group agreed 
the scope (Table 1) and was responsible for the completeness 
and appropriateness of the process, ensuring involvement of 
key stakeholder groups, approval of categorisation, group-
ing and phrasing of questions and interpretation of data. The 
protocol was prospectively published online at www.jla.nihr.
ac.uk/prior ity- setti ng- partn ershi ps/diabe tes- and- pregn ancy.
2.2 | Initial survey— identifying questions
Women and their support networks (partners, families, friends 
and carers) with experience of pregnancy or planning preg-
nancy with any type of diabetes and healthcare profession-
als were invited via an open survey (26 June– 15 November 
2019) to suggest up to three questions they felt were impor-
tant to answer. These could be any questions about the time 
before, during or after pregnancy with any type of diabetes. 
The scope was intentionally broad so that the submissions 
reflected public need.
The survey was available, in English, online and on paper. 
Targeted efforts to maximise responses, particularly from un-
derrepresented groups, included direct approaches in diabe-
tes and pregnancy clinics, outreach through relevant support 
groups, professional networks and conferences, diabetes, preg-
nancy and birth charities’ websites and communication chan-
nels and social media platforms. Concerted efforts were made 
to hear the voices of ethnic minorities working with organisa-
tions, support groups and community champions, which aim 
to address health inequalities. Representation across different 
ethnic minorities was monitored through broad groupings.
T A B L E  1  Scope of the James Lind Alliance priority setting partnership in diabetes and pregnancy
Questions about the following were included: Women, their partners, babies and families
Diabetes, including pre- existing diabetes of any type and subtype, and gestational diabetes
Time period in relation to pregnancy (i.e. preconception, antenatal, neonatal, post- natal and 
short- to long- term health outcomes)
Management of diabetes in pregnancy (i.e. screening, causes and prevention, diagnosis and 
treatment)
Physical, social, cultural, economic and psychological aspects
Co- morbidities and complications
Genetics, fertility and related aspects
Information, education and service improvement
Relevant to the UK population. This was intended to be a UK exercise with a UK focus.
Questions about the following were excluded: Pregnancy uncertainties not specific to diabetes
Care of the baby on a neonatal unit
Questions or priorities without a UK focus or relevance
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2.3 | Categorisation and grouping
The submitted questions were organised using NVivo 
qualitative data analysis software (QSR International Pty 
Ltd. Version 12, 2018). Initial data cleaning was manually 
completed with any issues about the clinical aspects or in-
terpretation of the submitted questions resolved with the 
steering group. The questions were analysed using content 
analysis with an initial stage of open coding of the ques-
tion content, followed by the grouping of codes into cat-
egories.15 To retain the integrity of the initial submissions, 
some questions were mapped to two or more categories. 
Independent second checks were conducted with members 
of the steering group to ensure potential impact of individ-
ual bias, and missed or misinterpreted categorisation was 
minimised. The steering group further consolidated the cat-
egories into groups and summarised the initial survey sub-
missions under an indicative question. Indicative questions 
were formulated to capture the issues raised by the submit-
ted questions within each group, whether originating from 
single or multiple respondents.
2.4 | Evidence checking
A broad level and pragmatic evidence checking strategy 
was taken (January – May 2020) with the aim of ascertain-
ing whether there was evidence of substantial uncertainty 
for each indicative question. The search was restricted 
to the Cochrane Database of Systematic Reviews (www.
cochr aneli brary.com), systematic reviews published since 
2017 using Medline or PubMed and National Institute of 
Clinical Excellence (NICE) and Scottish Intercollegiate 
Guidelines Network (SIGN) national diabetes and preg-
nancy guidelines.5,6 Expanded evidence searches, in-
cluding evidence highlighted by the steering group, were 
applied on a question- by- question basis after finalisation 
of the list of indicative questions. Research underway or 
recently completed but not available as published was not 
included as evidence. Where part of the question had suf-
ficient evidence, the question phrasing was amended to re-
flect the remaining uncertainty.
2.5 | Interim survey and prioritisation
The interim survey presented the long list of indicative 
questions in groups by phase. The order of the groups and 
individual questions within the groups were randomised 
each time the survey was entered. Participants were invited 
to pick up to 10 that they felt were most important to an-
swer. Due to the Covid- 19 pandemic and social distancing 
restrictions, the survey was offered online only. Following 
a pilot mid- May, the survey ran for nine weeks (29 May– 31 
July 2020).
2.6 | Interim ranking and shortlisting
Every selection made by an individual respondent had equal 
weighting and no weighting changes were made if fewer 
than 10 questions were selected. However, to account for the 
differences in observed voting patterns and the number of 
respondents from different groups, ranking was tallied sepa-
rately for: women and support networks, healthcare profes-
sionals, ethnic minorities and diabetes type, namely type 1, 
type 2 and other, and gestational diabetes. Within each of the 
groups, the total points for each question were put into rank 
order. The questions ranked in the top 10 for the two main 
groups (women/support networks and healthcare profession-
als), and the top three, and at least eight of the top 10, for each 
of the other subgroups, were shortlisted. In total, 18 questions 
were shortlisted for the final workshop, the maximum num-
ber considered feasible by the steering group for effective 
discussion online.
2.7 | Final workshop— agreeing the top 10
The final stage involved a 1- day workshop (2 October 2020) 
using the established JLA approach, which was adapted to 
be delivered online.14 Twenty- five participants were identi-
fied initially through phased targeted approaches to prioritise 
representation from ethnic minority groups, the devolved na-
tions and Crown dependencies, support networks and spe-
cific health professions, for example, psychologists and GPs 
as underrepresented groups, followed by open invitation. 
Contacts collated through the surveys, and special inter-
est groups and partner communication channels were used. 
Participants were screened for possible conflicts of interest 
and whether they were highly research active in the area. The 
participants were split into four breakout groups balanced by 
representation between women, support networks and health-
care professionals, and by experience of diabetes and health-
care specialist.
In breakout groups, the attendees participated in a se-
ries of discussion and ranking exercises to jointly rank the 
shortlist of indicative questions and agree the top 10 most 
important for future research to answer. The workshop and 
discussions were facilitated by trained JLA advisors to ensure 
equal and open participation. Four steering group members 
joined as observers only. Technical support was made avail-
able, and a contact point for emotional support was provided 
should any participant be upset by the process or discussions. 
The participants were invited to provide anonymous feedback 
on the prioritised questions and the workshop generally.
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2.8 | Ethics
The Medical Sciences Interdepartmental Research Ethics 
Committee, University of Oxford confirmed that the project 
did not require ethics committee approval.
3 |  RESULTS
The top 10 areas of most needed research in diabetes and preg-
nancy identified were: diabetes technology at any stage pre- to 
post- pregnancy, the best test for diabetes during pregnancy, diet 
and lifestyle interventions for diabetes management during preg-
nancy, emotional and well- being needs of women with diabetes 
pre- to post- pregnancy, safe birth at full term, post- natal care 
and support needs of women, diagnosis and management late in 
pregnancy, prevention of other types of diabetes in women with 
gestational diabetes, women's labour and birth experiences and 
choices and improving planning for pregnancy (Table 2).
The responses at each stage of the process are summarised 
in Figure  1. Participant demographics at each stage of the 
process are in Table  3. The survey submission counts and 
rankings for the 60 indicative questions are available in 
Supplementary Table S2.
3.1 | Initial survey
Four hundred and sixty- six responses were submitted (64% 
women and support networks, 32% healthcare profession-
als and 4% other/not answered) suggesting 1161 ques-
tions covering the whole perinatal period (Supplementary 
Table S3).
Initial questions submitted by women and support net-
works were mainly in relation to post- birth effects on 
themselves and their child, diabetes management during 
pregnancy and understanding the risks for diabetes in preg-
nancy. The long- term effects of diabetes in pregnancy on 
the child (risks of the child developing diabetes and any 
wider health effects) being the most frequently asked ques-
tion (20.1% of women and support networks’ submissions). 
This group more specifically raised questions about breast-
feeding (8.9%) and labour and birth (8.6%) in terms of in-
formed choice, continuity/availability of care and emotional 
support more generally. Healthcare professionals’ ques-
tions were mainly about pre- pregnancy care, and diagno-
sis and clinical management of diabetes in pregnancy. How 
to improve preconception care was most frequently asked 
(9.7% of healthcare professionals’ submissions), closely fol-
lowed by the value and methods of diagnosis and manage-
ment of diabetes late in pregnancy, that is, after 34 weeks 
(8.5%). Modes of delivering care, improving uptake and 
access to services and motivational interventions were more 
specifically raised by this group. Common to both groups 
were questions about individualised and risk- based care, 
optimal management of diabetes, prevention of diabetes and 
safety of medications.
One hundred and forty- two categories were extracted and 
broadly organised by the phase of pregnancy: pre- pregnancy 
(62 questions, 6.3%), pregnancy (376, 38.2%), labour and 
birth (87, 8.8%) and post- birth (373, 37.9%). Technology (20, 
2.0%), mental health and well- being (20, 2.0%) and health 
services (46, 4.7%) were identified as cross- cutting catego-
ries. A total of 934 questions were within scope, of which 
50 mapped to more than one category, and consolidated into 
60 indicative questions. Rarely was there a need to specify 
a type of diabetes within an indicative question, which re-
flects the significant overlap in priorities regardless of dia-
betes type. The main distinctions were questions relating to 
gestational diabetes, due to its transient nature and diagnosis 
in pregnancy. All 60 indicative questions were considered 
to have substantial uncertainty following evidence checks. 
The evidence check summary is provided in Supplementary 
Table S4.
3.2 | Interim survey
Six hundred and fourteen submissions (80% women and sup-
port networks and 20% healthcare professionals) were re-
ceived in the interim survey. In the interim survey rankings, 
there were notable differences between women and support 
networks, and healthcare professionals (Figure  2a). Four 
of the top 10 ranked questions for healthcare professionals 
were below the 45th ranking for women and support net-
works. Women and support networks ranked the long- term 
effects of diabetes in pregnancy on the child's general health 
(non- diabetes- related) highest. Varying standards and advice 
across hospitals and giving birth at full term were also in the 
top three.
Voting patterns varied for the main groups between sur-
veys (Figure 3) with overall movement towards labour and 
birth and cross- cutting categories. For example, despite 
being rarely asked in the initial survey, the use of technology 
became the highest ranked for healthcare professionals in the 
interim survey.
For ethnic minorities, representation was below national 
population figures for Black and Black British groups in both 
surveys (1.6% and 0.5% respectively; national 3.0%), and 
for Asian and Asian British groups (4.1%; national 7.0%) in 
the interim survey. With low numbers, the votes across 60 
questions became too dispersed to discern a strong pattern. 
However, peaks in voting overlapped the top 10 for women 
and support networks, and healthcare professionals, with the 
eight highest voted questions already shortlisted for the final 
workshop.
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F I G U R E  1  Summary of the James 
Lind Alliance prioritisation process showing 
how the top 10 questions in diabetes and 
pregnancy were identified. ^Ongoing studies 
were not included as evidence as it would 
not be possible to know if they answer the 
question









Total 466 614 25
Experience
Women with lived 
experience
287 (61.6) 473 (77.0) 9 (36.0)
Support network 11 (2.4) 20 (3.3) 2 (8.0)
Healthcare 
professionals
149 (32.0) 121 (19.7) 14 (56.0)
Other/not answered 19 (4.0) - - 
Living in
England 374 (85.8) 506 (82.4) 19 (76.0)
Scotland 25 (5.7) 29 (4.7) 0 (0.0)
Wales 15 (3.4) 22 (3.6) 5 (20.0)
Northern Ireland 8 (1.8) 24 (3.9) 1 (4.0)
Crown dependency 0 (0.0) 2 (0.3) 0 (0.0)
Not in the UK 7 (1.6) 25 (4.1) - 
Not answered 7 (1.6) 6 (1.0) - 
Age
19 years old or 
under
1 (0.2) 0 (0.0) - 
20 to 29 years old 79 (18.1) 92 (15.0) - 









40 years old or 
over
144 (33.0) 166 (27.0) - 
Not answered 11 (2.5) 6 (1.0) - 
Ethnicity
White 325 (74.5) 554 (90.2) 17 (68.0)
Asian and Asian 
British
59 (13.5) 25 (4.1) 5 (20.0)
Mixed and multiple 
ethnic groups
13 (3.0) 15 (2.4) 3 (12.0)
Black and Black 
British
7 (1.6) 3 (0.5) 0 (0.0)
Other 10 (2.3) 9 (1.5) 0 (0.0)
Not answered 22 (5.0) 8 (1.3) - 
Education levelb 
School (up to 
GCSE or 
equivalent)
26 (6.0) 11 (1.8) - 
School (A- levels or 
equivalent)
23 (5.3) 21 (3.4) - 
Higher education 
(e.g. college)
60 (13.8) 76 (12.4) - 
Degree level or 
higher
311 (71.3) 343 (55.9) - 
T A B L E  3  (Continued)
(Continues)
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Comparing the interim survey rankings by types of diabe-
tes, there were some clear differences (Figure 2b). Technology 
was ranked the top priority for type 1 and type 2/other diabe-
tes groups, but ranked low for the gestational diabetes group. 
Post- birth support came in second for type 1, but ranked low 
for both type 2/other and gestational diabetes groups, whereas 
testing for diabetes during pregnancy and prevention of de-
veloping diabetes ranked high for type 2/other and gestational 
diabetes groups but low for the type 1 diabetes group.
3.3 | Final workshop and top 10
The diversity and balance in experiences and expertise of 
workshop attendees were strong (Table 3). Participants un-
covered unexpected overlaps between questions, for exam-
ple, technology for diabetes care was considered to include 
telemedicine which was subsequently ranked lower; labour 
and birth choices was considered to overlap with safety of 
giving birth at full term and the need for induction. Groups 
also highlighted recurring themes that linked with multiple 
questions. For example, technology was considered to im-
prove understanding of diabetes management and reduce 
burden, linking with mental health and well- being. Therefore, 
with further such links highlighted, both these questions were 
more highly ranked as the discussions progressed.
Consistently, top ranking questions through the surveys 
were regarding the long- term health impact of maternal di-
abetes on the child. The questions submitted in the initial 
survey were clearly split into risk of the child developing 
diabetes or the risk of wider health conditions. Ranking in 
the top 10 of all groups, both questions were shortlisted for 
the final workshop. However, neither reached the final top 10 
(positions 11 and 12 respectively). Workshop discussions and 
post- workshop feedback from participants indicated several 
reasons for this apparent discrepancy. Firstly, the questions 
were considered to be addressed within the broader research 
agenda of child health, and not necessarily within pregnancy 
or women's health. The other questions all affected or con-
tributed to the child outcomes, so it was felt they would help 
address these questions too. Some participants considered 
that the answers to the questions about long- term child out-
comes would add burden to women already concerned by 
many factors associated with dealing with the responsibility 
of a pregnancy and diabetes. For some, ‘how can it be pre-
vented’ was important wording, as it balanced the concerns 
of adding burden of information on risks, with learning about 
what can be done to prevent these being realised. One of the 
questions did not include the specific wording about preven-
tion and so was ranked less highly. A further possible reason 
for these questions receiving less priority was because the 
votes were split; if presented as a single question, this may 
have meant a higher final ranking. A final possible reason 
may have been that the workshop consisted of people with 
recent experience, that is, within the last five years.
Feedback was received from 10 women and support net-
work representatives, and 10 healthcare professionals from 
the workshop:
‘It was really good having different perspectives. 
Moving to a second smaller group was also use-
ful, as it showed how varied priorities can be 
between 2 groups, despite having a similar mix 












Type 1 - 218 (27.6) 3 (25.0)
Type 2 - 88 (11.2) 3 (25.0)
Gestational - 406 (51.5) 4 (33.3)
Other, for example, 
MODY, LADA
- 39 (4.9) 2 (16.7)




- - 1 (7.1)
Diabetes Specialist 
Nurse
- - 2 (14.3)
Diabetes Specialist 
Midwife




- - 1 (7.1)





- - 1 (7.1)
Diabetologist - - 3 (21.4)
aUnfortunately, despite purposeful outreach, no expressions of interest were 
received from people with Black or Black British ethnicity or people living in 
Crown dependencies, and three people were invited from Scotland but withdrew 
at a later stage before the workshop. One of the women representatives had 
experience of pregnancy with Maturity Onset Diabetes of the Young (MODY), 
and another Latent Autoimmune Diabetes of Adulthood (LADA). The support 
network representatives, a sister and a husband, brought experience of type 1 
diabetes and type 2 diabetes respectively.
bDue to a technical error in the interim survey, the first 155 submissions did not 
have this question completed.
cIncluded in the interim survey to account for differences between priorities in 
relation to different types of diabetes. Multiple choice was enabled. Workshop 
data presented only for women and support network representatives. Some 
women had experience with more than one type of diabetes.
T A B L E  3  (Continued)
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‘Although the final top 10 was not the same as 
my personal top 10 that I had prepared, dis-
cussing all of the 18 questions, and reflecting 
on them as a group, meant I was satisfied with 
it. It was good to hear the views of women with 
different forms of diabetes and look at the ques-
tions from their perspective’.
Further excerpts of the feedback and the JLA’s review of the 
online format of the workshop are available at www.jla.nihr.
ac.uk/devel opmen t- of- onlin e- prior ity- setti ng- works hop.htm.
4 |  DISCUSSION
4.1 | Main findings
We supported women, their support networks and health-
care professionals to jointly identify the top 10 questions for 
research in diabetes and pregnancy. The final list includes 
priorities of relevance to all the stakeholders, all types of dia-
betes and preconception to long- term post- pregnancy. These 
questions were generated through a robust and inclusive pro-
cess, which can be trusted and used by funders of research 
and researchers to inform their research activities towards ad-
dressing evidence gaps of great need and impact.
There is consistency across many areas also identified by 
the modified prioritisation exercises in Canada and the USA 
focussing on gestational diabetes, such as screening, risk fac-
tors, prevention and clinical management of diabetes in the 
woman.10,11 For example, whether there is a better test for 
diabetes during pregnancy than the oral glucose tolerance 
test was ranked joint first for similar reasons of application, 
interpretation and practicality, with no apparent consensus 
on the thresholds, methods and timing to test for diabetes in 
pregnancy, due to small- sized studies. Our participants raised 
further questions such as the possible use of testing to predict 
gestational diabetes, the stratification of testing by risk and 
testing within special populations, such as those who have 
undergone gastric bypass surgery, and open up further oppor-
tunities for research.
There are also some clear differences in priorities in-
cluding preconception care, late pregnancy diagnosis, 
labour and birth experiences and post- natal care needs, 
particularly breastfeeding. The role of diabetes tech-
nology was ranked joint first position, and while expli-
cably not featuring in the gestational diabetes exercises, 
technology- specific questions formed the top three of the 
JDRF UK type 1 diabetes PSP final top 10. There have 
been significant developments in diabetes technology in 
the last few years with ongoing innovations.16 In the time 
since the final workshop, the National Institute of Clinical 
Excellence has completed their review and approved the 
F I G U R E  2  Interim survey question ranking comparisons between respondent groups. (a) Main groups: Indicative questions are ordered by 
rank position for women and support networks (60th to 1st place; left to right). (b) Diabetes type: Indicative questions are ordered by rank position 
for the group that indicated interest/experience in gestational diabetes (60th to 1st place; left to right). ‘Other’ types were grouped with type 2 
diabetes due to low number and greatest similarity in rankings. T1D – Type 1 diabetes; T2D – Type 2 diabetes; GDM – Gestational diabetes mellitus
F I G U R E  3  Survey submissions by main group. The initial and 
interim survey submissions for women and support networks, and 
healthcare professionals proportioned by phase of pregnancy
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funding of continuous glucose monitoring for pregnant 
women with type 1 diabetes, in line with The NHS Long 
Term Plan.17,18 However, our results endorse their recom-
mendations for further large- scale research in different 
monitoring methods and systems (i.e. insulin pumps) in 
women with diabetes of different types, through all stages 
preconception to post- pregnancy, and importantly with 
wider population diversity. There are also wider facets to 
consider such as apps, automation, data integration plat-
forms and data sharing in supporting the management of 
diabetes.
Risks to the child's health was the number one priority 
identified by women in the Canadian exercise, and ranked 
highest in the USA exercise, but strikingly fell outside our top 
10. However, the possible reasons for this, based on differ-
ential prioritisation of two related summary questions, made 
clear that the impact on the child is still considered highly 
important for separate study.
Important overarching issues were noted around continu-
ity of care and support (particularly post- birth), consistency 
in care standards and advice, joint decision making (particu-
larly in labour and birth) and the burden for women of being 
diagnosed with and managing diabetes. The consequences 
on women's well- being and mental health were at the core 
of much of the discussion at the final workshop. The initial 
survey submissions also raised further unanswered questions 
about the impact of a ‘medicalised’ pregnancy, withdrawal 
of intensive clinical involvement postpartum and support 
needs of women if adverse outcomes in their child linked 
to diabetes are realised. There is ongoing lack of evidence 
on the support pregnant women with diabetes may need as 
previously echoed by the gestational diabetes prioritisation 
exercises. However, the Diabetes UK Too Often Missing re-
port highlights pregnancy as a time of particular high risk 
for emotional and psychosocial impact of diabetes requiring 
increased awareness and support.19
5 |  STRENGTHS AND 
LIMITATIONS
This is the first priority setting exercise to focus on all differ-
ent types of diabetes and at any stage before, during and after 
pregnancy, including long- term post- pregnancy.
The initial survey was completed in 2019 before the 
Covid- 19 pandemic and lockdowns, but the interim prioriti-
sation survey and final workshop took place during the pan-
demic over 2020. Due to the restrictions, the interim survey 
and final workshop could only be completed online. Despite 
an increased response rate in the interim survey, the online- 
only nature will have imposed limitations on who could take 
part. Reliance on online- only means of communication and 
participation may also have affected outreach, particularly 
to ethnic minority groups, which was achieved in the initial 
survey mainly through the support of community champions 
and face- to- face approaches in hospital clinics. However, 
despite our best efforts, representation was below what may 
be expected based on national population statistics, particu-
larly Black and Black British groups.20 Therefore, the results 
may not be representative of the priorities of ethnic minority 
groups.
Although the indicative questions were established before 
the 2020 Covid- 19 pandemic, it is possible that the voting in 
the interim survey and, consequently, the shortlist of ques-
tions for the final workshop have been influenced. The final 
workshop participants were advised to consider the short-
listed questions thinking longer term beyond the pandemic 
so that this would not unduly influence the results for the 
future. More generally, it is not assured that if the exercise 
was redone that the same priorities would be identified and 
assigned the same rank.
6 |  CONCLUSIONS
Further research is needed to provide evidence- based health-
care for women, with or at risk of diabetes complications, 
who are planning pregnancy or are pregnant, to ensure the 
best outcomes for them and their children in the short and 
long term.
The Covid- 19 pandemic has highlighted the importance 
of inclusive research. Pregnant women, those planning preg-
nancy or breastfeeding are often actively excluded from clini-
cal trials, perpetuating the population as a vulnerable group.21 
The addition of co- morbidities, such as diabetes, complicates 
matters further. As well as improved health and well- being 
for generations of families, interventions which improve out-
comes for pregnancy with diabetes provide significant oppor-
tunity in terms of cost savings.13
The questions identified are areas that still have signifi-
cant uncertainty and are considered to be of most importance 
by the beneficiaries of that research. This work presents fur-
ther opportunity for funders and researchers to focus future 
research to address the priorities of women, support networks 
and health professionals.
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